1 week Ago By Defense World Staff
Bank of Montreal Can trimmed its position in shares of Invesco Biotechnology & Genome ETF ( NYSEARCA:PBE – Free Report ) by 78.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 730 shares of the company’s stock after selling 2,735 shares during the quarter.
Bank of Montreal Can’s holdings in Invesco Biotechnology & Genome ETF were worth $49,000 at the end of the most recent quarter. Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co.
boosted its stake in shares of Invesco Biotechnology & Genome ETF by 30.0% in the fourth quarter. JPMorgan Chase & Co.
now owns 650 shares of the company’s stock valued at $43,000 after purchasing an additional 150 shares during the period. Millstone Evans Group LLC purchased a new position in Invesco Biotechnology & Genome ETF in the 4th quarter valued at approximately $64,000. Jones Financial Companies Lllp grew its stake in shares of Invesco Biotechnology & Genome ETF by 52.
9% in the fourth quarter. Jones Financial Companies Lllp now owns 2,315 shares of the company’s stock worth $154,000 after acquiring an additional 801 shares in the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the fourth quarter worth $161,000.
Finally, Jane Street Group LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at $295,000. Invesco Biotechnology & Genome ETF Trading Down 0.0 % NYSEARCA:PBE opened at $61.
08 on Friday. The stock has a fifty day moving average price of $63.25 and a 200 day moving average price of $66.
83. Invesco Biotechnology & Genome ETF has a 12-month low of $54.52 and a 12-month high of $72.
84. The firm has a market cap of $219.89 million, a PE ratio of 21.
05 and a beta of 0.83. Invesco Biotechnology & Genome ETF Company Profile PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index).
The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. Featured Articles Five stocks we like better than Invesco Biotechnology & Genome ETF Do ETFs Pay Dividends? What You Need to Know Markets Think Robinhood Earnings Could Send the Stock Up Differences Between Momentum Investing and Long Term Investing Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Quiet Period Expirations Explained AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.
com's FREE daily email newsletter ..
